文献速递肝病

FXR激动剂PX20606通过靶向血管重塑和肝窦功能障碍改善门静脉高压

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
PubMed 文献 · J Hepatol · 2016-12-18

在非肝硬化和肝硬化门静脉高压大鼠模型中,非甾体选择性FXR激动剂PX20606灌胃可降低门静脉压力、减轻肝纤维化与血管重塑、改善肝窦功能障碍和肠屏障功能;体外实验显示其可上调人肝窦内皮细胞eNOS和DDAH表达。

要点

  • PX20606降低非肝硬化PPVL大鼠门静脉压力(12.6±1.7 vs 10.4±1.1mmHg,p=0.020)。
  • PX20606降低肝硬化CCl4大鼠门静脉压力(15.2±0.5 vs 11.8±0.4mmHg,p=0.001)。
  • PX20606减少肝硬化大鼠纤维化面积、羟脯氨酸及促纤维化蛋白表达。

核心结论

  • 非甾体FXR激动剂PX20606通过减少肝纤维化、血管重塑和肝窦功能障碍改善门静脉高压。

研究设计与样本

  • 在非肝硬化(部分门静脉结扎,PPVL,7天)和肝硬化(四氯化碳,CCl4,14周)门静脉高压实验模型中,PX20606(10mg/kg)或甾体FXR激动剂奥贝胆酸(OCA,10mg/kg)灌胃给药。
  • 检测门静脉压力、肝内血管阻力、肝纤维化和细菌易位。
  • 在人肝窦内皮细胞中检测PX20606对eNOS和DDAH表达的影响。

主要发现

  • PX降低非肝硬化PPVL大鼠门静脉压力(12.6±1.7 vs 10.4±1.1mmHg;p=0.020)。
  • PX降低肝硬化CCl4大鼠门静脉压力(15.2±0.5 vs 11.8±0.4mmHg;p=0.001)。
  • PPVL动物PX治疗后细菌易位减少36%(p=0.041),脂多糖结合蛋白降低30%(p=0.024),内脏肿瘤坏死因子α水平降低39%(p=0.044)。
  • CCl4大鼠PX降低纤维化天狼星红面积43%(p=0.005)、肝脏羟脯氨酸66%(p<0.001)及促纤维化蛋白(Col1a1、α平滑肌肌动蛋白、转化生长因子β)表达。
  • CCl4-PX大鼠转氨酶水平显著降低,肝脏巨噬细胞浸润减少;PX诱导肝窦血管舒张并减少肝内血管收缩。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Steroidal farnesoid X receptor (FXR) agonists demonstrated potent anti-fibrotic activities and lowered portal hypertension in experimental models. The impact of the novel non-steroidal and selective FXR agonist PX20606 on portal hypertension and fibrosis was explored in this study. METHODS: In experimental models of non-cirrhotic (partial portal vein ligation, PPVL, 7days) and cirrhotic (carbon tetrachloride, CCl4, 14weeks) portal hypertension, PX20606 (PX,10mg/kg) or the steroidal FXR agonist obeticholic acid (OCA,10mg/kg) were gavaged. We then measured portal pressure, intrahepatic vascular resistance, liver fibrosis and bacterial translocation. RESULTS: PX decreased portal pressure in non-cirrhotic PPVL (12.6±1.7 vs. 10.4±1.1mmHg; p=0.020) and cirrhotic CCl4 (15.2±0.5 vs. 11.8±0.4mmHg; p=0.001) rats. In PPVL animals, we observed less bacterial translocation (-36%; p=0.041), a decrease in lipopolysaccharide binding protein (-30%; p=0.024) and splanchnic tumour necrosis factor α levels (-39%; p=0.044) after PX treatment. In CCl4 rats, PX decreased fibrotic Sirius Red area (-43%; p=0.005), hepatic hydroxyproline (-66%; p<0.001), and expression of profibrogenic proteins (Col1a1, α smooth muscle actin, transforming growth factor β). CCl4-PX rats had significantly lower transaminase levels and reduced hepatic macrophage infiltration. Moreover, PX induced sinusoidal vasodilation (upregulation of cystathionase, dimethylaminohydrolase (DDAH)1, endothelial nitric oxide synthase (eNOS), GTP-cyclohydrolase1) and reduced intrahepatic vasoconstriction (downregulation of endothelin-1, p-Moesin). In cirrhosis, PX improved endothelial dysfunction (decreased von-Willebrand factor) and normalized overexpression of vascular endothelial growth factor, platelet-derived growth factor and angiopoietins. While short-term 3-day PX treatment reduced portal pressure (-14%; p=0.041) by restoring endothelial function, 14week PX therapy additionally inhibited sinusoidal remodelling and decreased portal pressure to a greater extent (-22%; p=0.001). In human liver sinusoidal endothelial cells, PX increased eNOS and DDAH expression. CONCLUSIONS: The non-steroidal FXR agonist PX20606 ameliorates portal hypertension by reducing liver fibrosis, vascular remodelling and sinusoidal dysfunction. LAY SUMMARY: The novel drug PX20606 activates the bile acid receptor FXR and shows beneficial effects in experimental liver cirrhosis: In the liver, it reduces scarring and inflammation, and also widens blood vessels. Thus, PX20606 leads to an improved blood flow through the liver and decreases hypertension of the portal vein. Additionally, PX20606 improves the altered intestinal barrier and decreases bacterial migration from the gut.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Schwabl P, Hambruch E, Seeland BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2016. PMID: 27993716. doi:10.1016/j.jhep.2016.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。